Bone Metastases of Endometrial Carcinoma Treated by Surgery: Report on 13 Patients and Review of The Medical Literature

Abstract Objective: The aim of this study was to describe the clinicopathological features of EC patients with bone metastases treated with surgery and to systematically review the literature. Methods: We performed a retrospective study to include patients with bone metastases of EC at Peking University People’s Hospital during 2000 to 2019. Clinicopathological features and survival outcomes were collected.Results: Among the 1662 patients with EC, 14 (0.84%) were identified with bone metastases, and all were treated surgically. 13 cases were analyzed. Four had bone metastases when diagnosed; and the remaining 9 cases had bone metastases when first relapsed with the median time to recurrence of 13 months (range, 5-144). The median age of the 13 patients was 58 years old (range, 45-76). Twelve were endometrioid carcinoma. The majority sites of bone metastases were pelvis, followed by the spine. The median overall survival (OS) was 57 months. We further combined the 13 patients with another 24 cases identified from literature research. There was no significant difference in clinicopathological characteristics between the patients with bone metastases when diagnosed and when first relapsed. The median OS was numerically longer for patients with bone metastases when diagnosed than when first relapsed (57 vs. 36 months, P=0.084). The median OS was significantly longer in patients with endometrioid carcinoma than in those with type II carcinoma (57 vs. 4 months, P=0.003). Conclusions: Patients with bone metastases of EC might benefit from comprehensive treatment based on surgery, as symptoms can be palliated and survival can be extended probably.